Vasoactive intestinal peptide.
Said SI.
J Endocrinol Invest. 1986 Apr;9(2):191-200. doi: 10.1007/BF03348097.
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma.
Ravindranathan S, Passang T, Li JM, Wang S, Dhamsania R, Ware MB, Zaidi MY, Zhu J, Cardenas M, Liu Y, Gumber S, Robinson B, Sen-Majumdar A, Zhang H, Chandrakasan S, Kissick H, Frey AB, Thomas SN, El-Rayes BF, Lesinski GB, Waller EK.
Nat Commun. 2022 Oct 27;13(1):6418. doi: 10.1038/s41467-022-34242-4.
Vasoactive Intestinal Peptide-Secreting Tumors: A Review.
Siddappa PK, Vege SS.
Pancreas. 2019 Oct;48(9):1119-1125. doi: 10.1097/MPA.0000000000001402.
Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report.
Nilubol N, Freedman EM, Quezado MM, Patel D, Kebebew E.
J Clin Endocrinol Metab. 2016 Oct;101(10):3564-3567. doi: 10.1210/jc.2016-2051. Epub 2016 Sep 1.
Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male.
Abu-Zaid A, Azzam A, Abudan Z, Algouhi A, Almana H, Amin T.
Hematol Oncol Stem Cell Ther. 2014 Sep;7(3):109-15. doi: 10.1016/j.hemonc.2014.03.002. Epub 2014 Apr 29.
Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer.
Raderer M, Kurtaran A, Yang Q, Meghdadi S, Vorbeck F, Hejna M, Angelberger P, Kornek G, Pidlich J, Scheithauer W, Virgolini I.
J Nucl Med. 1998 Sep;39(9):1570-5.
Acute pancreatitis.
Geokas MC, Baltaxe HA, Banks PA, Silva J Jr, Frey CF.
Ann Intern Med. 1985 Jul;103(1):86-100. doi: 10.7326/0003-4819-103-1-86.
A case of vasoactive intestinal peptide-secreting tumor (VIPoma) arising from MEN1 inactivation which recurred 15 years after the initial resection.
Sakurai M, Wakabayashi T, Kondo Y, Ikeda E, Watanabe K, Takei A, Okazaki H, Okada K, Ebihara K, Kakiuchi N, Ogawa S, Fukushima N, Ishibashi S.
Endocr J. 2023 Jun 28;70(6):573-579. doi: 10.1507/endocrj.EJ22-0578. Epub 2023 Mar 9.
Pancreatic neuroendocrine tumors.
Batcher E, Madaj P, Gianoukakis AG.
Endocr Res. 2011;36(1):35-43. doi: 10.3109/07435800.2010.525085.
Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours.
Hessenius C, Bäder M, Meinhold H, Böhmig M, Faiss S, Reubi JC, Wiedenmann B.
Eur J Nucl Med. 2000 Nov;27(11):1684-93. doi: 10.1007/s002590000325.
